APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>AIM Vaccine is looking to raise US$1bn in its upcoming Hong Kong IPO. The deal is run by Goldman Sachs, CICC, China Securities, and Macquarie. This is a refiling after its filing in July 2021 was rejected by HKEX.</p><p>AIM Vaccine is a leading vaccine company covering the full value chain from research to manufacturing and commercialisation. As of the latest practicable date (3 Sept 2021), it had commercialised eight vaccine products against six disease areas. It also has 23 vaccine candidates against 13 disease areas. The firm has four Licensed Manufacturing Facilities in Rong’an Bio, AIM Hanxin, AIM Kanghuai and AIM Weixin, and a total designed annual production capacity of 91.3m doses.</p>

AIM Vaccine is looking to raise US$1bn in its upcoming Hong Kong IPO. The deal is run by Goldman Sachs, CICC, China Securities, and Macquarie. This is a refiling after its filing in July 2021 was rejected by HKEX.AIM Vaccine is a leading vaccine company covering the full value chain from research to manufacturing and commercialisation. As of the latest practicable date (3 Sept 2021), it had commercialised eight vaccine products against six disease areas. It also has 23 vaccine candidates against 13 disease areas. The firm has four Licensed Manufacturing Facilities in Rong’an Bio, AIM Hanxin, AIM Kanghuai and AIM Weixin, and a total designed annual production capacity of 91.3m doses.

AIM Vaccine (艾美疫苗) Pre-IPO Tearsheet (Refiled)